Key person interview

Question 1. How did you look back at 2021?

2021 will be the year when we will start our own sales, and we will sell all the products that have been sold by Eisai. Selling it yourself means nothing more than promoting the proper use of TREAKISYM by providing the necessary and sufficient information for its proper use.
I thought that the quality of information provision had declined, or that there was no provision of information in the first place, and I thought that such things should not happen, so I reviewed the way of information provision. Therefore, what we were conscious of was to deliver the high-quality information necessary for proper use, and in particular, because anticancer drugs inevitably cause side effects, we should provide information on side effect management to doctors for proper use. I did my best to tell you. Appropriate use of TREAKISYM is believed to provide the benefit of the possibility of long-term survival for patients. I was conscious of that point when I started self-selling, and I still feel the same way.
On the other hand, due to the influence of the corona virus, we are unable to visit hospitals or meet with doctors frequently. Until then, I could have met if I had gone to the hospital and waited, but according to the doctors, even if they requested an appointment, it became a situation where they didn't have to meet with people who didn't need to meet. Yes, we are now in a situation where we can select an MR to interview. I think this is the biggest impact of Corona. I believe that the most important thing is to convey the idea that we are providing information on proper use with the patient's benefit in mind, and to have them fully understand. With that in mind, I wanted the TM (Treakisym Manager) to make an effort to provide information.

Question 2. Regarding the approval of RI (bolus injection) administration, what would you like to convey to the medical field?

Patients undergoing anticancer drug treatment have the highest desire to receive cancer treatment while living a normal life and live in their own way. Of course, the most important thing is to cure cancer, but the blood cancer called follicular lymphoma is one of the cancers that cannot be cured. Because cancer is incurable, there is a strong need for people to live their own lives while undergoing treatment.
The fact that the administration time can be shortened from 60 minutes to 10 minutes by administering RI does not simply shorten the time, but it is possible to reduce the troublesome feeling of spending a long time in the hospital or waiting for a long time. There is a nature. I believe that such small things can support the patient's feelings toward treatment. I believe that it will be a single dosage form and single administration method that will alleviate patients' feelings of dislike and troublesome treatment and encourage them to move forward with treatment. From this point of view, we believe that we must spread the use of 10-minute dosing as soon as possible.

Question 3. How did you conduct sales activities for TREAKISYM in conjunction with the expanded indication for relapsed/refractory DLBCL (diffuse large B-cell lymphoma)?

The treatment of relapsed and refractory DLBCL is extremely difficult, and although various drugs have been tried in the past, new drugs and treatment methods have not been approved. TREAKISYM has been taking on the challenge of adding indications for relapsed and refractory DLBCL for some time, ^but thanks to the passion of our employees and the cooperation of many institutions and doctors who participated in clinical trials, we have finally made it to the clinical stage. Ready to use. At the same time, a drug called polatuzumab vedotin was approved for the same indication at the same time, and polatuzumab, rituximab, and bendamustine combination therapy (P-BR therapy) became available in clinical settings. The availability of these two new options has had a great impact on the doctors who are responsible for treatment, and I think that's why expectations were very high. In order to respond to that, we thought that although our words are simple, we would do our best to clearly communicate how to use the product and its benefits to patients.
However, on the other hand, due to the corona crisis, the sales style, method, and form of information provision have changed significantly, and it is a time when the TREAKISYM industry ^has changed. If you rely only on such things, you won't be able to make a lot of money, or you won't be able to get what you want. For that reason, for example, decide what day and what day of the week you will hold a web briefing, and do it in a series of 8 times in a row for 4 weeks. So, since all the contents are the same, I would like to ask you to ask somewhere and make sure to consider this treatment method. We hold commemorative lectures on the additional indications of DLBCL more than ten times, weekly, weekly, and the professors say, Do you want to do it?" I did it so much.
Thanks to that, I was able to ask when I wanted to, so I think that the information spread to the doctors at once and led to prescriptions.

Question 4. From a marketing and sales standpoint, please tell us that you have finally achieved operating income through the introduction and switching to liquid formulations and increased sales to DLBCL.

Question 5. Please tell us about online sales activities in promoting the self-selling system, and what you noticed and episodes at academic conferences and lectures.

The information provision activities of pharmaceutical companies are centered on the provision of information about products, such as "This effect has been confirmed" and "Please be careful about this side effect." TREAKISYM has been widely used for the past 10 years, and many doctors know how to use it, but ^the provision of information on proper use remains important. In promoting proper use, rather than simply conveying information about the effects and side effects of products, we should think about delivering information necessary for proper use from the perspective of patients, pharmacists, and nurses. I am thinking about planning lectures with creative content, such as the theme of issues in the treatment of diseases. I feel that the content of the lecture, which clarifies the theme, has been relatively evaluated by many medical professionals.
As activities for academic societies in 2021, we co-sponsored seminars at three academic societies: the Japanese Society for Hematopoietic Cell Transplantation (currently the Japanese Society for Transplantation and Immunotherapy), the Lymphoreticuloendothelial Society, and the Japanese Society of Hematology. In addition, since SymBio has released a liquid formulation, we also co-sponsored a seminar with the Japanese Society of Clinical Oncology.
Academic conferences continue to be held during the COVID-19 pandemic, but many conferences are being held as hybrids, and the form of participation in academic conferences has become more diverse. think. I feel that I have to think about a plan based on that point.

Question 6. Are promotional activities changing from providing information through MRs to providing information through websites, online seminars, and academic conferences for medical professionals?

I don't know too many companies, but I think there are many pharmaceutical companies that have created websites for medical professionals and have a lot of resources called MRs. At SymBio, we believe that the important thing in the fusion of digital utilization and real information provision through people is that if the activities through people are not properly done, information provision through digital will not be useful. If the doctor evaluates the MR as a trustworthy MR through repeated interviews with the MR, even in a situation where visits to hospitals are becoming more difficult, the MR will want to meet with the MR through a web interview. I think that it will be like that, such as confirming with the MR and confirming only what is really necessary in an interview with the MR. Of course, it is also important to enrich the content of information provided through digital media. I don't think that pharmaceutical companies' information provision will be completely digital, but on the other hand, I don't think there will be a return to an era where information is provided only through people. I think that many companies are exploring how to use these SymBio properly. I feel that it would have been easier to introduce information provision more proactively.

Question 7. As the head of the marketing department, how do ^you feel about the patients and their families who are being treated with TREAKISYM?

I joined the company in 2015, but when I heard that such a good drug was not being delivered to patients properly, ^I joined the company hoping to somehow deliver TREAKISYM to as many patients as possible. I still feel that way.
Of course, TREAKISYM is highly effective, but the side effects that occur during treatment are very mild compared to ^conventional treatments. Anti-cancer drug treatment often results in hair loss and disgust, making the treatment disgusting. I think it's a benefit for you.
​^I believe that TREAKISYM treatment is the most suitable treatment for fighting cancer while living a normal life. I want to come

Question 8. As the person in charge of the marketing department, would you like to say something to shareholders?

Until now, SymBio Pharmaceuticals has been able to continue its business with the support of so many people, and in order to respond to such people, I would like ^to place importance on delivering TREAKISYM to patients. I believe that these activities will lead to the prescription of drugs, which will lead to the company's performance, and to respond to the wishes of the many medical professionals who have supported us and our shareholders.
Now that ^we have a self-selling system in place, we have achieved profitability for the entire company by providing TREAKISYM to promote proper use. I would like to carry out my activities on a daily basis, never forgetting that I am responding to the wishes of our shareholders.